Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.

Détails

Ressource 1Télécharger: 29344270_BIB_13DAD73D00CC.pdf (399.79 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_13DAD73D00CC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program.
Périodique
Journal of Cancer
Auteur⸱e⸱s
Balmelli C., Railic N., Siano M., Feuerlein K., Cathomas R., Cristina V., Güthner C., Zimmermann S., Weidner S., Pless M., Stenner F., Rothschild S.I.
ISSN
1837-9664 (Print)
ISSN-L
1837-9664
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
9
Numéro
2
Pages
250-255
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
javax.xml.bind.JAXBElement@5a6991ed
Differentiated thyroid cancer (DTC) accounts for approximately 95% of thyroid carcinomas. In the metastatic RAI-refractory disease, chemotherapy has very limited efficacy and is associated with substantial toxicity. With increasing knowledge of the molecular pathogenesis of DTC, novel targeted therapies have been developed. Lenvatinib is a tyrosine kinase inhibitor (TKI) with promising clinical activity based on the randomized phase III SELECT trial. In Switzerland, a Named Patient Program (NPP) was installed to bridge the time gap to Swissmedic approval. Here, we report the results from the Swiss Lenvatinib NPP including patients with metastatic RAI-refractory DTC. javax.xml.bind.JAXBElement@7407c55a Main inclusion criteria for the Swiss NPP were RAI-refractory DTC, documented disease progression, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The number of previous therapies was not limited. The Swiss Lenvatinib NPP was initiated in June 2014 and was closed in October 2015 with the approval of the drug. javax.xml.bind.JAXBElement@1c5cb2cc Between June 2014 and October 2015, 13 patients with a median age of 72 years have been enrolled. Most patients (69%) had at least one prior systemic therapy, mainly sorafenib. 31% of patients showed a PR and 31% SD. Median progression free survival was 7.2 months and the median overall survival was 22.7 months. Dose reduction due to adverse events was necessary in 7 patients (53%). At the time of analysis 6 patients (47%) were still on treatment with a median time on treatment of 9.98 months. javax.xml.bind.JAXBElement@713fc2d4 Our results show that lenvatinib has reasonable clinical activity in unselected patients with RAI-refractory thyroid cancer with nearly two-third of patients showing clinical benefit. The toxicity profile of lenvatinib is manageable.

Mots-clé
differentiated thyroid cancer, lenvatinib, radioiodine refractory, sorafenib., tyrosine kinase inhibitors
Pubmed
Web of science
Open Access
Oui
Création de la notice
27/01/2018 13:25
Dernière modification de la notice
03/04/2023 10:43
Données d'usage